Latest News and Press Releases

Pasithea begins PAS-004 Phase 1/1b NF1 trial in Australia, with U.S. and S. Korea sites planned. First dosing set for Q2 2025. 48.5% R&D refund expected.

Pasithea Tx' PAS-004 shows up to 91% pERK inhibition in Phase 1 trial; one pancreatic cancer patient sees 4+ months stable disease and tumor shrinkage.

Pasithea Therapeutics completes Cohort 6 enrollment and dosing in Phase 1 PAS-004 trial for MAPK-driven advanced cancers; full enrollment by 2025.

Pasithea Tx (Nasdaq: KTTA) will present updated Phase 1 data for MEK inhibitor PAS-004 in MAPK-driven cancers at ASCO 2025 on June 2 in Chicago.

Pasithea’s PAS-004 cancer trial clears safety review; no DLTs or rash seen, advancing to 30mg dose in Phase 1 for MAPK-driven tumors.

Pasithea opens EU trial sites for PAS-004, doses Cohort 4, and plans interim safety data in Q1 2025.

Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.

Pasithea Therapeutics' PAS-004 shows positive Phase 1 data: well-tolerated, no toxicities, promising efficacy in NF1 and MAPK-driven cancers.

Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing

Pasithea Therapeutics will present at H.C. Wainwright’s Global Investment Conference, highlighting PAS-004 development for NF1 and cancer.